Results 81 to 90 of about 122,678 (147)

SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study

Current Issues in Pharmacy and Medical Sciences
SARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that SARS-CoV-2 is able to cross the blood-brain barrier. Researchers have also discovered that SARS-CoV-2 can infect glial cells.
Brzozowski Michal, Kolesnik Marcin, Michalski Aleksander, Drop Katarzyna, Polz-Dacewicz Malgorzata   +4 more
doaj   +1 more source

Pre-existing IgG antibodies to HCoVs NL63 and OC43 Spike increased during the pandemic and after COVID-19 vaccination

Heliyon
Preexisting immunity may be associated with increased protection against non-related pathogens such as, SARS-CoV-2. There is little information regarding endemic human coronaviruses (HCOVs) from Pakistan, which experienced a relatively low COVID-19 ...
Zahra Hasan, Kiran Iqbal Masood, Marc Veldhoen, Shama Qaiser, Marta Alenquer, Mishgan Akhtar, Sadaf Balouch, Junaid Iqbal, Yaqub Wassan, Shahneel Hussain, Khalid Feroz, Sajid Muhammad, Atif Habib, Akbar Kanji, Erum Khan, Afsar Ali Mian, Rabia Hussain, Maria Joao Amorim, Zulfiqar A. Bhutta   +18 more
doaj   +1 more source

The SARS-CoV-2 antibody-dependent enhancement façade

Microbes and Infection
Antibody-dependent enhancement (ADE) is an immunological paradox whereby sensitization following a primary viral infection results in the subsequent enhancement of a similar secondary infection. This idiosyncratic immune response has been established in dengue virus infections, driven by four antigenically related serotypes co-circulating in endemic ...
Jeremia M. Coish, Lori A. MacNeil, Adam J. MacNeil   +2 more
openaire   +2 more sources

Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies

Harm Reduction Journal
Background During the initial wave of the COVID-19 pandemic, there was a surprisingly low incidence of SARS-CoV-2 among People Who Use Drugs (PWUD) in Oslo, Norway, despite their heightened vulnerability regarding risk of infection and severe courses of ...
Linda Elise Couëssurel Wüsthoff, Fridtjof Lund-Johansen, Kathleen Henriksen, Gull Wildendahl, Jon-Aksel Jacobsen, Leni Gomes, Hina Sarwar Anjum, Regine Barlinn, Anne-Marte Bakken Kran, Ludvig Andre Munthe, John T. Vaage   +10 more
doaj   +1 more source

Human antibodies can neutralize SARS-CoV-2 [PDF]

Nature Reviews Immunology, 2020
openaire   +2 more sources

Down‐regulation of SARS‐CoV‐2 neutralizing antibodies in vaccinated smokers

MedComm, 2022
Jiahui Zhang, Fei Teng, Xiaomei Zhang, Hongye Wang, Te Liang, Shubin Guo, Xiaobo Yu   +6 more
doaj   +1 more source

Detection of SARS-CoV-2 antibodies in companion animals in Poland during the post-pandemic period (2022-2025). [PDF]

BMC Vet Res
Turlewicz-Podbielska H, Czyżewska-Dors E, Adaszek Ł, Ruszkowski JJ, Pomorska-Mól M.   +4 more
europepmc   +1 more source

Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies. [PDF]

Methods Protoc
Nakhanova G, Chervyakova O, Shorayeva K, Issabek A, Moldagulova S, Zhunushov A, Ulankyzy A, Zhakypbek A, Omurtay A, Nakhanov A, Absatova Z, Shayakhmetov Y, Jekebekov K, Baiseit T, Kerimbayev A.   +14 more
europepmc   +1 more source

Waning antibodies to SARS-CoV-2 – Don't panic

The Lancet Regional Health - Europe, 2021
openaire   +4 more sources

Antibody response to SARS-CoV-2 booster vaccines

Clinical Biochemistry, 2022
Loving, Hanna S., Sacks, David B., Harb, Roa   +2 more
openaire   +2 more sources